Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 3
1(20.0%)
5Total
Phase 1(4)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03002428Phase 3Completed

A Comparison of PF708 and Forteo in Osteoporosis Patients

Role: lead

NCT02655549Phase 1Completed

A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects

Role: lead

NCT02656810Phase 1Completed

A Comparison Study of PF708 and Forteo in Healthy Subjects

Role: lead

NCT02121353Phase 1Completed

Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration

Role: lead

NCT02474134Phase 1Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Role: lead

All 5 trials loaded